Literature DB >> 33067554

Left ventricular remodeling and dysfunction in primary aldosteronism.

Cheng-Hsuan Tsai1,2, Chien-Ting Pan2,3, Yi-Yao Chang4, Zheng-Wei Chen2,3, Vin-Cent Wu5, Chi-Sheng Hung2,6, Yen-Hung Lin7,8.   

Abstract

Primary aldosteronism (PA) is a common cause of secondary hypertension and is associated with worse cardiovascular outcomes. The elevated aldosterone in PA leads to left ventricular (LV) remodeling and dysfunction. In recent decades, clinical studies have demonstrated worse LV remodeling including increased LV mass and cardiac fibrosis in patients with PA compared to patients with essential hypertension. Several mechanisms may explain the process of aldosterone-induced LV remodeling, including directly profibrotic and hypertrophic effects of aldosterone on myocardium, increased reactive oxygen species and profibrotic molecules, dysregulation of extracellular matrix metabolism, endothelium dysfunction and circulatory macrophages activation. LV remodeling causes LV diastolic and systolic dysfunction, which may consequently lead to clinical complications such as heart failure, atrial fibrillation, ischemic heart disease, and other vascular events. Adequate treatment with adrenalectomy or medical therapy can improve LV remodeling and dysfunction in PA patients. In this review, we discuss the mechanisms of aldosterone-induced LV remodeling and provide an up-to-date review of clinical research about LV remodeling-related heart structural changes, cardiac dysfunction, and their clinical impacts on patients with PA.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33067554      PMCID: PMC7895762          DOI: 10.1038/s41371-020-00426-y

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  106 in total

1.  Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

Authors:  G P Rossi; A Sacchetto; P Visentin; C Canali; G R Graniero; P Palatini; A C Pessina
Journal:  Hypertension       Date:  1996-05       Impact factor: 10.190

2.  Long-term cardio- and cerebrovascular events in patients with primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Chiara Bertello; Andrea Viola; Davide Tizzani; Andrea Iannaccone; Valentina Crudo; Jacopo Burrello; Alberto Milan; Franco Rabbia; Franco Veglio
Journal:  J Clin Endocrinol Metab       Date:  2013-09-20       Impact factor: 5.958

3.  Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma.

Authors:  Yen-Hung Lin; Lian-Yu Lin; Aaron Chen; Xue-Ming Wu; Jen-Kuang Lee; Ta-Chen Su; Vin-Cent Wu; Shih-Chieh Chueh; Wei-Chou Lin; Men-Tzung Lo; Pa-Chun Wang; Yi-Lwun Ho; Kwan-Dun Wu
Journal:  Atherosclerosis       Date:  2011-12-08       Impact factor: 5.162

4.  Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.

Authors:  G P Rossi; A Sacchetto; E Pavan; P Palatini; G R Graniero; C Canali; A C Pessina
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

Review 5.  Prevalence and diagnosis of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

6.  Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study.

Authors:  Zheng-Wei Chen; Kuan-Chih Huang; Jen-Kuang Lee; Lung-Chun Lin; Ching-Way Chen; Yi-Yao Chang; Che-Wei Liao; Vin-Cent Wu; Chi-Shen Hung; Yen-Hung Lin
Journal:  J Hypertens       Date:  2018-02       Impact factor: 4.844

7.  Role of aldosterone in left ventricular hypertrophy in hypertension.

Authors:  Kiyoshi Matsumura; Koji Fujii; Hideyuki Oniki; Masayo Oka; Mitsuo Iida
Journal:  Am J Hypertens       Date:  2006-01       Impact factor: 2.689

8.  Cardiovascular outcomes in patients with primary aldosteronism after treatment.

Authors:  Cristiana Catena; GianLuca Colussi; Elisa Nadalini; Alessandra Chiuch; Sara Baroselli; Roberta Lapenna; Leonardo A Sechi
Journal:  Arch Intern Med       Date:  2008-01-14

9.  Long term outcome of Aldosteronism after target treatments.

Authors:  Vin-Cent Wu; Shuo-Meng Wang; Chia-Hui Chang; Ya-Hui Hu; Lian-Yu Lin; Yen-Hung Lin; Shih-Chieh Jeff Chueh; Likwang Chen; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

10.  Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients.

Authors:  Che-Wei Liao; Lian-Yu Lin; Chi-Sheng Hung; Yen-Tin Lin; Yi-Yao Chang; Shuo-Meng Wang; Vin-Cent Wu; Kwan-Dun Wu; Yi-Lwun Ho; Fumitoshi Satoh; Yen-Hung Lin
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

View more
  12 in total

Review 1.  Primary Aldosteronism and Ischemic Heart Disease.

Authors:  Shivaraj Patil; Chaitanya Rojulpote; Aman Amanullah
Journal:  Front Cardiovasc Med       Date:  2022-05-23

2.  Treatment of Primary Aldosteronism and Reversal of Renin Suppression Improves Left Ventricular Systolic Function.

Authors:  Troy H Puar; Chin Kai Cheong; Roger S Y Foo; Seyed Ehsan Saffari; Tian Ming Tu; Min Ru Chee; Meifen Zhang; Keng Sin Ng; Kang Min Wong; Andrew Wong; Foo Cheong Ng; Tar Choon Aw; Joan Khoo; Linsey Gani; Thomas King; Wann Jia Loh; Shui Boon Soh; Vanessa Au; Tunn Lin Tay; Eberta Tan; Lily Mae; Jielin Yew; Yen Kheng Tan; Khim Leng Tong; Sheldon Lee; Siang Chew Chai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

3.  Editorial: Diagnosis and Treatment of Primary Aldosteronism: from Clinical Origin to Translational Research.

Authors:  Wan-Chen Wu; Qiang Wei; Vin-Cent Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

4.  Diabetes mellitus is associated with worse baseline and less post-treatment recovery of arterial stiffness in patients with primary aldosteronism.

Authors:  Cheng-Hsuan Tsai; Xue-Ming Wu; Che-Wei Liao; Zheng-Wei Chen; Chien-Ting Pan; Yi-Yao Chang; Bo-Ching Lee; Yu-Wei Chiu; Tai-Shuan Lai; Vin-Cent Wu; Chi-Shen Hung; Yen-Hung Lin
Journal:  Ther Adv Chronic Dis       Date:  2022-01-13       Impact factor: 5.091

Review 5.  Atrial Fibrillation and Aortic Ectasia as Complications of Primary Aldosteronism: Focus on Pathophysiological Aspects.

Authors:  Martina Bollati; Chiara Lopez; Fabio Bioletto; Federico Ponzetto; Ezio Ghigo; Mauro Maccario; Mirko Parasiliti-Caprino
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 6.  Strain Imaging for the Early Detection of Cardiac Remodeling and Dysfunction in Primary Aldosteronism.

Authors:  Yilin Chen; Tingyan Xu; Jianzhong Xu; Limin Zhu; Dian Wang; Yan Li; Jiguang Wang
Journal:  Diagnostics (Basel)       Date:  2022-02-20

7.  Inhibition of GTPase Rac1 expression by vitamin D mitigates pressure overload-induced cardiac hypertrophy.

Authors:  Ali Moradi; Abdulbaset Maroofi; Mahdie Hemati; Tahmine Hashemzade; Nasrin Alborzi; Fatemeh Safari
Journal:  Int J Cardiol Heart Vasc       Date:  2021-11-30

8.  Differences in Glycemic Abnormalities Between Primary Aldosteronism and Essential Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Worapaka Manosroi; Pichitchai Atthakomol; Pittaporn Wattanawitawas; Supawan Buranapin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 6.055

9.  New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies.

Authors:  Cheng-Hsuan Tsai; Ya-Li Chen; Chien-Ting Pan; Yen-Tin Lin; Po-Chin Lee; Yu-Wei Chiu; Che-Wei Liao; Zheng-Wei Chen; Chin-Chen Chang; Yi-Yao Chang; Chi-Sheng Hung; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

10.  CMR-Verified Myocardial Fibrosis Is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients.

Authors:  Fangli Zhou; Tao Wu; Wei Wang; Wei Cheng; Shuang Wan; Haoming Tian; Tao Chen; Jiayu Sun; Yan Ren
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.